CN117794572A - 用于治疗感染后自身免疫性糖尿病的方法 - Google Patents

用于治疗感染后自身免疫性糖尿病的方法 Download PDF

Info

Publication number
CN117794572A
CN117794572A CN202280044277.7A CN202280044277A CN117794572A CN 117794572 A CN117794572 A CN 117794572A CN 202280044277 A CN202280044277 A CN 202280044277A CN 117794572 A CN117794572 A CN 117794572A
Authority
CN
China
Prior art keywords
day
dose
course
treatment
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280044277.7A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗西斯科·莱昂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Previnson Biology Ltd
Original Assignee
Previnson Biology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Previnson Biology Ltd filed Critical Previnson Biology Ltd
Publication of CN117794572A publication Critical patent/CN117794572A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN202280044277.7A 2021-05-24 2022-05-24 用于治疗感染后自身免疫性糖尿病的方法 Pending CN117794572A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
US63/192,414 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
CN117794572A true CN117794572A (zh) 2024-03-29

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280044277.7A Pending CN117794572A (zh) 2021-05-24 2022-05-24 用于治疗感染后自身免疫性糖尿病的方法

Country Status (10)

Country Link
US (1) US20220372146A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024521164A (cg-RX-API-DMAC7.html)
KR (1) KR20240023522A (cg-RX-API-DMAC7.html)
CN (1) CN117794572A (cg-RX-API-DMAC7.html)
AU (1) AU2022283272A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219473A1 (cg-RX-API-DMAC7.html)
IL (1) IL308627A (cg-RX-API-DMAC7.html)
MX (1) MX2023013849A (cg-RX-API-DMAC7.html)
WO (1) WO2022251258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005213449A1 (en) * 2004-02-04 2005-08-25 The La Jolla Institute For Allergy And Immunology Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
JP2009544761A (ja) * 2006-06-14 2009-12-17 マクロジェニクス,インコーポレーテッド 低毒性免疫抑制モノクローナル抗体を用いて自己免疫疾患を治療する方法
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
JP7137696B2 (ja) * 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を予防するための方法および組成物
WO2021035054A1 (en) * 2019-08-20 2021-02-25 Precision Biosciences, Inc. Lymphodepletion dosing regimens for cellular immunotherapies
KR20230092863A (ko) * 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023013851A (es) * 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20230382993A1 (en) * 2022-05-24 2023-11-30 Provention Bio, Inc. Methods and compositions for preventing or delaying type 1 diabetes

Also Published As

Publication number Publication date
JP2024521164A (ja) 2024-05-28
US20220372146A1 (en) 2022-11-24
CA3219473A1 (en) 2022-12-01
WO2022251258A1 (en) 2022-12-01
IL308627A (en) 2024-01-01
AU2022283272A1 (en) 2023-12-07
EP4347021A4 (en) 2025-04-23
EP4347021A1 (en) 2024-04-10
MX2023013849A (es) 2023-12-08
KR20240023522A (ko) 2024-02-22

Similar Documents

Publication Publication Date Title
US12565529B2 (en) Methods for treating type 1 diabetes
US20250304688A1 (en) Methods and Compositions Comprising Anti-CD3 Antibodies and DYRK1A Inhibitors for Treating Diabetes
US20260008850A1 (en) Methods for delaying onset of type 1 diabetes
US20220372146A1 (en) Methods for treating post infectious autoimmune diabetes
WO2024182767A1 (en) Methods and compositions for treating type 1 diabetes comprising teplizumab and verapamil
AU2021287998A1 (en) Methods and compositions for preventing type 1 diabetes
WO2024206739A1 (en) Methods for reducing exogenous insulin use
AU2023275531C1 (en) Methods and compositions for preventing or delaying type 1 diabetes
EP4532552A1 (en) Methods and compositions for preventing or delaying type 1 diabetes
CN117940162A (zh) 用于治疗糖尿病的包含抗cd3抗体和dyrk1a抑制剂的方法和组合物
KR20260046157A (ko) 1형 당뇨병을 치료하기 위한 방법
CN118591558A (zh) 用于预防或推迟第1型糖尿病的方法及组合物
BR122024027421A2 (pt) Uso de teplizumabe e método de prognóstico de responsividade de um anticorpo anti-cd3 no retardamento do início do diabetes tipo 1 (t1d)
HK40053741A (en) Methods and compositions for preventing type 1 diabetes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination